KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Equivalents (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Cash & Equivalents data on record, last reported at $338.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 1.12% year-over-year to $338.3 million; the TTM value through Sep 2025 reached $338.3 million, up 1.12%, while the annual FY2024 figure was $242.1 million, 39.37% down from the prior year.
  • Cash & Equivalents reached $338.3 million in Q3 2025 per IONS's latest filing, up from $297.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $869.2 million in Q4 2021 and bottomed at $242.1 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $407.5 million, with a median of $348.9 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: surged 118.57% in 2021, then plummeted 68.19% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $869.2 million in 2021, then tumbled by 68.19% to $276.5 million in 2022, then soared by 44.41% to $399.3 million in 2023, then plummeted by 39.37% to $242.1 million in 2024, then surged by 39.77% to $338.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $338.3 million in Q3 2025, $297.3 million in Q2 2025, and $264.2 million in Q1 2025.